Trial Profile
A multi-dose, double-blind, parallel-group study of the effects of dose titration and administration with food on the tolerability of SCA-136 [vabicaserin] in healthy subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2007
Price :
$35
*
At a glance
- Drugs Vabicaserin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Wyeth
- 23 Jan 2007 New trial record.